News
Regulatory tailwind from the FDA in OI
Klas Palin
2026-11-19
11:37 CET
The FDA has granted Medivir rare paediatric disease designation (RPDD) for MIV-711 in osteogenesis imperfecta (OI). In our view, the designation strengthens the programme’s regulatory profile and adds a potential source of significant future value through a Priority Review Voucher (PRV). However, aside from the timing, we do not view the announcement as unexpected, given the encouraging preclinical efficacy data, supportive findings from prior clinical studies of MIV-711 and the characteristics of the target disease.
What’s new? Medivir has received RPDD from the FDA for MIV-711 in OI. In our view, this further strengthens the programme’s regulatory profile, adding to the orphan drug designations previously granted for MIV-711 in both OI and Perthes disease.
What does it mean? To obtain RPDD, a company must provide the FDA with a scientific rationale and data supporting the potential efficacy of the drug in the relevant disease. In this case, the application was supported by data from an animal model, in which MIV-711 improved bone strength, quality and morphology, as well as clinical data generated in osteoarthritis that are relevant to patients with OI. An important benefit of RPDD is that it may qualify MIV-711 for a PRV upon approval. A PRV can be sold to another pharma or biotech company, allowing the recipient to secure priority FDA review, which shortens the target review period from 10 to six months. Several recent PRV transactions have been valued at around USD200m.
What do we do? This is clearly positive, providing a further potential source of income for MIV-711. We currently model a USD150m sale of a PRV in 2032 and risk-adjust this in line with the OI programme, using a likelihood of approval of 20%, with an additional 50% reduction to reflect the PRV programme’s current sunset date of 30 September 2029. We note, however, that the programme could be extended again.